Cellular Biomedicine Group

Cellular Biomedicine Group is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. It is the result of the acquisition, transfer, commercialization, and advancement of thirty years of research and human treatment experience in cellular medicine. Its cellular research and development is the result of collaboration among scientists and doctors from the US, England, and China.

Merck

Novartis

Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront

ROCKVILLE, Md. and SHANGHAI, Feb. 19, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") today announced the completion of the merger (the "Merger") of the Company with CBMG Merger Sub Inc., a Delaware corporation ("Merger Sub") and a...

Cellular Biomedicine Group, Inc. Announces Completion of Merger

ROCKVILLE, Md. and SHANGHAI, Feb. 8, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") announced that, at the Company's special meeting of stockholders held today, its stockholders approved the proposal to adopt the previously announced...

Cellular Biomedicine Group, Inc. Stockholders Approve Merger

ROCKVILLE, Md. and SHANGHAI, Jan. 28, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company," "CBMG," "we" or "our"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases,...

Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed Merger

NEW YORK, Jan. 24, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CBMG to members of CBMG management. If you are a CBMG investor, and would like...

Lifshitz Law Firm, P.C. Announces Investigation of CBMG, CIT, HMSY, INFO, PS, SPWH, UROV, and WDR

NEW YORK, Dec. 17, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CBMG to members of CBMG management. If you are a CBMG investor, and would like...

Lifshitz Law Firm, P.C. Announces Investigation of CBMG, CBLI, CLCT, EIGI, FBM, HDS, IPHI and PNM

GAITHERSBURG, Md. and SHANGHAI, Dec. 4, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today...

Cellular Biomedicine Group Announces Data to be Presented at 2020 ASH Annual Meeting

GAITHERSBURG, Md. and SHANGHAI, Nov. 9, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported...

Cellular Biomedicine Group Reports Q3 2020 Financial Results and Business Highlights

CBMG agreed to be taken private at $19.75 per share in cash. The transaction is subject to shareholder approval as well as CFIUS clearance.

Cellular Biomedicine Group, Inc.: 10% Return In A Few Months As Merger Should Receive Approval

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a...

ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm - CBMG, VRTU, MR, IMMU, JCAP

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating: Rosetta Stone Inc. (NYSE: RST) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Cambium Learning Group for $30 per share.

INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm – RST, CBMG, AIMT, AKCA

NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc.

Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc.

PHILADELPHIA, Aug. 14, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Cellular Biomedicine Group, Inc.

Kaskela Law LLC Announces Investigation of Cellular Biomedicine Group, Inc. (CBMG) and Encourages CBMG Shareholders to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) and its board of directors concerning the proposed acquisition of the company by members of Cellular Biomedicine Group’s senior management and other investors.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Cellular Biomedicine Group, Inc.

NEW YORK, Aug. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cellular Biomedicine Group, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Cellular Biomedicine Group, Inc.

NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Cellular Biomedicine Group, Inc.

CELLULAR BIOMEDICINE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CBMG and Encourages Investors to Contact the Firm

Cellular Biomedicine Group (CBMG) Reports Q2, H1 2020 Financial Results and Business Highlights

New York, New York--(Newsfile Corp. - August 12, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cellular Biomedicine Group, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Cellular Biomedicine Group, Inc. - CBMG

Cellular Biomedicine Group (CBMG) Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

GAITHERSBURG, Md. and SHANGHAI, July 13, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, provided an...

Cellular Biomedicine Group (CBMG) Hosts R&D Showcase and Provides Updates to Clinical Programs

GAITHERSBURG, Md. and SHANGHAI, June 30, 2020 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced it...

Cellular Biomedicine Group (CBMG) to Host Investor R&D Showcase Highlighting Updates to Clinical Programs

GAITHERSBURG, Md. and SHANGHAI, June 29, 2020 /PRNewswire/ -- Cellular Biomedicine Group Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced...

Cellular Biomedicine Group (CBMG) Announces Results of 2020 Annual Meeting of Stockholders

Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q1 2020 Results - Earnings Call Transcript

Cellular Biomedicine Group's (CBMG) CEO Tony Liu on Q4 2019 Results - Earnings Call Transcript

Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q3 2019 Results - Earnings Call Transcript

News for Cellular Biomedicine Group Stock (CBMG)